Logo

TKNO

Alpha Teknova, Inc.

TKNO

Alpha Teknova, Inc. • NASDAQ
$4.68 ▼ -1.47% (-0.07)
Market Cap $250.52 M
52w High $10.37
52w Low $3.94
Dividend Yield 0%
P/E -14.18
Volume 71.69K
Outstanding Shares 53.53M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $10.454M ▲ $7.223M ▼ $-4.286M ▼ -40.999% ▼ $-0.08 ▼ $-2.426M ▼
Q2-2025 $10.287M ▲ $7.37M ▼ $-3.57M ▲ -34.704% ▲ $-0.067 ▲ $-1.796M ▲
Q1-2025 $9.795M ▲ $7.971M ▲ $-4.645M ▲ -47.422% ▲ $-0.087 ▲ $-3.384M ▲
Q4-2024 $9.265M ▼ $7.756M ▲ $-5.719M ▲ -61.727% ▲ $-0.11 ▲ $-3.983M ▲
Q3-2024 $9.576M $7.522M $-7.565M -79% $-0.17 $-5.761M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $3.204M ▼ $107.625M ▼ $34.975M ▲ $72.65M ▼
Q2-2025 $24M ▼ $110.487M ▼ $34.43M ▼ $76.057M ▼
Q1-2025 $26.273M ▼ $113.993M ▼ $35.388M ▼ $78.605M ▼
Q4-2024 $30.396M ▼ $118.769M ▼ $36.375M ▼ $82.394M ▼
Q3-2024 $31.691M $124.099M $36.831M $87.268M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-4.286M ▼ $-1.88M ▲ $1.64M ▼ $168K ▲ $-72K ▲ $-2.267M ▲
Q2-2025 $-3.57M ▲ $-2.101M ▲ $2.028M ▼ $-28K ▲ $-101K ▲ $-2.308M ▲
Q1-2025 $-4.645M ▲ $-4.103M ▼ $3.824M ▲ $-52K ▲ $-331K ▲ $-4.309M ▼
Q4-2024 $-5.719M ▲ $-936K ▲ $-1.414M ▲ $-87K ▼ $-2.437M ▲ $-1.503M ▲
Q3-2024 $-7.565M $-2.059M $-25.759M $15.367M $-12.451M $-2.39M

Revenue by Products

Product Q4-2024Q1-2025Q2-2025Q3-2025
Clinical Solutions
Clinical Solutions
 $0 ▲$0 ▲$0 ▲$0 ▲
Lab Essentials
Lab Essentials
 $10.00M ▲$10.00M ▲$10.00M ▲$10.00M ▲
Other Product
Other Product
 $0 ▲$0 ▲$0 ▲$0 ▲

Five-Year Company Overview

Income Statement

Income Statement Teknova looks like a small, early‑stage commercial company with revenues that have been fairly flat over the last few years. Gross profit is positive but modest, and operating costs are high relative to the size of the business, so the company has been running steady losses since shortly after going public. The depth of those losses appears to have peaked and has been gradually shrinking, which suggests some cost discipline or better mix, but the business is still clearly in “build and scale” mode rather than in a mature profit phase. Earnings per share remain negative, so current shareholders are effectively funding the company’s growth and capacity build‑out.

Balance Sheet

Balance Sheet The balance sheet shows a company that bulked up its asset base after the IPO and then has slowly drawn it down while trying to grow into its new capacity. Cash has come down meaningfully from earlier levels, while debt has ticked up but still looks moderate compared with total equity, so leverage does not appear extreme. Equity remains positive, but it has eroded over time as losses accumulate. Overall, the financial position looks acceptable for a young growth company but clearly not “cash rich,” which makes the path to profitability and disciplined capital use important watch points.

Cash Flow

Cash Flow Teknova has not yet reached the point where its operations fund themselves. Operating cash flow has been consistently negative, indicating that the core business still consumes cash. Free cash flow has been even more negative at times because of sizeable investments in facilities and equipment, particularly around the new manufacturing site. More recently, capital spending appears to have eased, so cash burn looks lower than during the heaviest investment period, but the company still likely needs either improving margins or additional capital over time if losses persist.

Competitive Edge

Competitive Edge Competitively, Teknova occupies a specialized niche rather than trying to compete head‑on with the very large life science suppliers. Its edge is in custom, made‑to‑order reagents delivered quickly, with strong quality and regulatory credentials. The focus on cell and gene therapy, and on helping customers move from research‑grade to clinical‑grade materials, positions it in a high‑growth corner of the market. Against that, the company faces giants with deep resources and broad portfolios, so maintaining its speed, flexibility, and close customer relationships is crucial to preserving its differentiation. Its success will likely hinge on whether it can convert these specialized capabilities into a larger, more diversified and recurring customer base.

Innovation and R&D

Innovation and R&D Teknova’s story leans heavily on innovation in process and product rather than on blockbuster drugs. It has invested in a modern, automated, GMP‑certified plant and a modular manufacturing platform that allows it to produce many different custom reagents efficiently. Offerings like the online custom buffer configurator and AAV‑focused solutions show a clear attempt to solve specific bottlenecks for gene therapy and advanced therapy developers. The company is also working on new tools and assays to support viral vector production. Overall, it appears to be channeling substantial effort into making workflows faster and more reliable for customers, with an emphasis on quality systems and scalability rather than raw R&D spend alone.

Summary

Teknova is a small, specialized life‑science supplier that has built real technical and operational capabilities—particularly in fast, custom, GMP‑ready reagents for cell and gene therapy—but is still in the loss‑making, investment‑heavy phase of its life. Revenues are modest and relatively steady, margins are improving but not yet sufficient to cover the cost base, and cash outflows have reduced from earlier peaks but remain a key constraint. The balance sheet can support operations for now, yet it is clearly not over‑capitalized, so progress toward self‑funding growth will matter. Strategically, the company’s niche, customization strength, and focus on emerging therapies create a promising runway, while dependence on a developing market, competition from much larger players, and ongoing cash burn are the main risks to monitor.

NEWS

November 6, 2025 · 4:01 PM UTC

Teknova Reports Third Quarter 2025 Financial Results

Read more

October 28, 2025 · 4:01 PM UTC

Teknova to Report Third Quarter 2025 Financial Results on November 6, 2025

Read more